Whilst this is concordant with the diploid nature of BRAF mutant/MSI serrated pathway cancers with CIMP which progress via a high mutational rate, it does not explain how BRAF mutant/MSS serrated pathway cancers progress and especially the fact that their prognosis is particularly poor [16], [29], [30], [31], [32]. This evidence concerns the gene BRAF and cancer.